Laekna Obesity Drug Begins Clinical Study

Like
Comment
Favorite

Laekna Obesity Drug Begins Clinical Study

MT Newswires Live2024-11-28

Laekna (HKG:2105) advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.

LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays (RGA) aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2486399739?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-28 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486399739","market":"us","top_or_hot":-1,"title":"Laekna Obesity Drug Begins Clinical Study","media":"MT Newswires Live","content":"<html><body><p> Laekna (HKG:2105) advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.</p><p>LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays (RGA) aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laekna Obesity Drug Begins Clinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaekna Obesity Drug Begins Clinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-28 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Laekna (HKG:2105) advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.</p><p>LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays (RGA) aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4019","symbol_name":"再保险","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486399739","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486399739","pubTimestamp":1732789883,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Laekna  advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays  aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4019":"再保险","RGA":"美国再保险集团","BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"Laekna肥胖药物开始临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":0.9,"RGA":1},"content_text":"Laekna (HKG:2105) advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays (RGA) aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}